Bactericidal Activity of Rifampin-Amikacin against Mycobacterium ulcerans in Mice

Author:

Dega Herve1,Bentoucha Abdelhalim1,Robert Jerome1,Jarlier Vincent1,Grosset Jacques1

Affiliation:

1. Faculte de Medecine Pitie-Salpetriere, Service de Bacteriologie et Hygiene, 75634 Paris Cedex 13, France

Abstract

ABSTRACT To identify the most active curative treatment of Buruli ulcer, two regimens incorporating the use of rifampin (RIF) were compared with the use of RIF alone in a mouse footpad model of Mycobacterium ulcerans infection. Treatments began after footpad swelling from infection and continued for 12 weeks with five doses weekly of one of the following regimens: (i) 10 mg of RIF/kg alone; (ii) 10 mg of RIF/kg and 100 mg of amikacin (AMK)/kg; and (iii) 10 mg of RIF/kg, 100 mg of clarithromycin (CLR)/kg, and 50 mg of sparfloxacin (SPX)/kg. The activity of each regimen was assessed in terms of the reduction of the average lesion index and acid-fast bacillus (AFB) and CFU counts. All three regimens displayed various degrees of bactericidal activity against M. ulcerans . The ranking of bactericidal activity was found to be as follows: RIF-AMK > RIF-CLR-SPX > RIF. RIF-AMK was able to cure M. ulcerans -infected mice and prevent relapse 26 weeks after completion of treatment. To determine the impact of different rhythms of administration of RIF-AMK on the suppression of M.ulcerans growth, mice were given the RIF-AMK combination for 4 weeks but doses were administered either 5 days a week or twice or once weekly. After completion of treatment, the mice were kept under supervision for 30 additional weeks. M. ulcerans was considered to have grown in the footpad if swelling was visually observed and harvests contained more than 5 × 10 5 AFB per footpad. The proportion of mice in which growth of M. ulcerans occurred, irrespective of drug dosage, was compared with the control mice to determine the proportion of M. ulcerans killed. Each dosage of RIF-AMK was bactericidal for M. ulcerans ( P < 0.001), but the effect was significantly stronger in mice treated 5 days per week. The promising results of RIF-AMK treatment in M. ulcerans -infected mice support the clinical trial that is currently in progress under World Health Organization auspices in Ghana.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Reference21 articles.

1. Activities of New Macrolides and Fluoroquinolones against Mycobacterium ulcerans Infection in Mice

2. Colston, M. J., G. R. F. Hilson, and D. K. Bannerjee. 1978. The proportional bactericidal test, a method for assessing bactericidal activity of drugs agaisnt Mycobacterium leprae in mice. Lepr. Rev.49:7-15.

3. Dega, H., J. Robert, P. Bonnafous, V. Jarlier, J. Grosset. 2000. Activity of several antimicrobials on Mycobacterium ulcerans infection in mice. Antimicrob. Agents Chemother.44:2070-2073.

4. Feldman, W. H., and A. G. Karlson. 1957. Mycobacterium ulcerans infections: response to chemotherapy in mice. Am. Rev. Tuberc.75:266-279.

5. Fenner, F. 1956. Pathogenic behavior of Mycobacterium ulcerans and Mycobacterium balnei in mouse and developing chick embryo. Am. Rev. Tuberc.73:650-673.

Cited by 76 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3